Skip to main contentAI and Advanced
/
BIOCON · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
BI
NSE · Equity shares · Biotechnology & Drugs5.60 · 1.50%
Biocon BIOCON
NSE:INR 380
BSE:INR 380
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for BIOCON
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 374.4
Day rangeINR 370.5 — INR 382
52-week rangeINR 331 — INR 447.15
Volume30.43 L
Market cap71,299.12
P/E129.24
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)16,927
Net Income (INR Cr)385.6
Rev Growth (5 Year %)18.83
EPS Growth (5 Year %)-14.56
P/E Ratio129.24
Book Value32.25
EPS5.34
Price/BV11.78Computed
Research path: Interpret Biocon's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
BIOCONBiocon1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 63,650.6 | 58,797.3 | 56,070.7 |
| Accumulated Depreciation Total | -7,989.9 | -6,796.2 | -5,915.1 |
| Cash Equivalents | 1,311.1 | 1,277.9 | 69.8 |
| Other Liabilities Total | 1,434.9 | 3,448.8 | 1,620.8 |
| Accrued Expenses | 943.6 | 913.1 | 513.9 |
| Long Term Debt | 10,746.3 | 12,405.4 | 12,932.4 |
| Common Stock Total | 810.5 | 600.3 | 600.3 |
| Other Equity Total | 2,795.4 | 947.2 | 590.9 |
| Other Current Assets Total | 22.6 | 99.2 | 138.9 |
| Prepaid Expenses | 242.4 | 189.9 | 157.1 |
| Total Assets | 63,650.6 | 58,797.3 | 56,070.7 |
| Current Portof LT Debt/Capital Leases | 584.5 | 1,962.8 | 702.7 |
| Additional Paid-In Capital | 15,560 | 258.1 | 228.5 |
| Cash | 1,104.9 | 1,948.8 | 1,163.6 |
| Total Equity | 34,031.8 | 21,644 | 19,783.7 |
| Long Term Investments | 1,439.9 | 747 | 754.2 |
| Retained Earnings(Accumulated Deficit) | 14,393 | 19,491 | 18,140.1 |
| Treasury Stock-Common | -42.3 | -78.4 | -97.1 |
| Total Common Shares Outstanding | 161.95 | 120.06 | 120.06 |
| Property/Plant/Equipment Total-Gross | 22,653.4 | 20,210.3 | 17,892.9 |
| Tangible Book Valueper Share Common Eq | 32.25 | -45.09 | -57.27 |
| Goodwill Net | 18,377.5 | 16,785.7 | 16,372.4 |
| Total Liabilities | 29,618.8 | 37,153.3 | 36,287 |
| Total Debt | 15,434.1 | 18,362 | 16,276.7 |
| Short Term Investments | 1,781.6 | 1,338 | 1,340.4 |
| Cashand Short Term Investments | 4,197.6 | 4,564.7 | 2,573.8 |
| Total Receivables Net | 6,517.9 | 6,324.3 | 7,259.1 |
| Notes Payable/Short Term Debt | 3,566.3 | 3,454.7 | 2,149.2 |
| Deferred Income Tax | 241.7 | 357.7 | 391.5 |
| Accounts Receivable-Trade Net | 5,986.8 | 5,487.9 | 6,230.6 |
| Property/Plant/Equipment Total-Net | 14,663.5 | 13,414.1 | 11,977.8 |
| Minority Interest | 2,589.7 | 6,068.5 | 5,491.1 |
| Total Current Liabilities | 14,069.2 | 14,333.8 | 15,358.8 |
| Total Inventory | 6,199.3 | 5,108.1 | 5,050.3 |
| ESOP Debt Guarantee | 514.3 | 424.9 | 320.1 |
| Accounts Payable | 7,213.2 | 6,970.7 | 6,816.8 |
| Other Currentliabilities Total | 1,761.6 | 1,032.5 | 5,176.2 |
| Total Long Term Debt | 11,283.3 | 12,944.5 | 13,424.8 |
| Intangibles Net | 10,431.6 | 10,271.9 | 10,286.7 |
| Other Long Term Assets Total | 889.8 | 473.3 | 592.3 |
| Note Receivable-Long Term | 668.5 | 819.1 | 908.1 |
| Unrealized Gain(Loss) | 0.9 | 0.9 | 0.9 |
| Total Current Assets | 17,179.8 | 16,286.2 | 15,179.2 |
| Capital Lease Obligations | 537 | 539.1 | 492.4 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %28.06
Margins
Operating Margin 12m6.47
Operating Margin 5y Avg12.97
Net Profit Margin 12m2.18
Net Profit Margin 5y6.8
Yield
Dividend Yield %0.12
Valuation
Price to Sale Ratio4.21
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk26.75
Analyst consensus
ConsensusHold
Consensus score2.75
Analyst opinions16
Strong Sell count2
Sell count3
Hold count3
Buy count5
Strong Buy count3
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 44.68%
- FII
- 8.14%
- MF
- 15.47%
- Other
- 31.71%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders - markets.businessinsider.comMarket news · 21 Jul 2026, 11:15 am
Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders markets.businessinsider.com
Biocon Malaysia Gets EMA Approval to Supply Semglee Insulin to Europe - Medical DialoguesMarket news · 18 Jul 2026, 4:52 pm
Biocon Malaysia Gets EMA Approval to Supply Semglee Insulin to Europe Medical Dialogues
Price to book forward of Natural Biocon (India) Ltd. – BSE:NATURAL - TradingViewMarket news · 17 Jul 2026, 8:52 pm
Price to book forward of Natural Biocon (India) Ltd. – BSE:NATURAL TradingView
JSA, TT&A, Baker & McKenzie advise brokers on Mylan Inc's ₹3,679 crore exit from Biocon - Bar and BenchMarket news · 17 Jul 2026, 11:11 am
JSA, TT&A, Baker & McKenzie advise brokers on Mylan Inc's ₹3,679 crore exit from Biocon Bar and Bench
"Claire Mazumdar beats me from the credentials point of view. She has a great CV. But I told her, earn your stripes and she earned it. So, once she did that, I felt she is a worthy successor," said Biocon's Kiran Mazumdar Shaw at Future Female Forward reflecti - LinkedInMarket news · 16 Jul 2026, 2:17 pm
"Claire Mazumdar beats me from the credentials point of view. She has a great CV. But I told her, earn your stripes and she earned it. So, once she did that, I felt she is a worthy successor," said Biocon's Kiran Mazumdar Shaw at Future Female Forward reflecti LinkedIn
Biocon Shares Hit 52-Week High, Up 3% on EMA Nod - EquitypanditMarket news · 16 Jul 2026, 12:31 pm
Biocon Shares Hit 52-Week High, Up 3% on EMA Nod Equitypandit
Corporate actions
Events
- annual General MeetingAGM
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.0.5000 per share(10%)Final Dividend
- annual General MeetingPOM
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- annual General MeetingEGM
Rusaka Markets Community
Discussion and sentiment for Biocon
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- BIOCON
- BSE Code
- 532523
Questions
Stock FAQ
What is the symbol and ISIN of Biocon?
Biocon has the symbol BIOCON and ISIN - INE376G01013.
What is the current price of Biocon?
Biocon is currently trading at INR 380.00.
What are the year high and year low of Biocon?
Biocon has a year high of INR 447.15 and a year low of INR 331.00.
What is the market capitalization of Biocon?
Biocon has a market capitalization of INR 71,299.12 crore.
What is the P/E ratio of Biocon?
Biocon has a P/E ratio of 129.24.
What is the dividend yield of Biocon?
Biocon has a dividend yield of 0.12%.
How is the financial performance of Biocon based on revenue, net income, and EPS?
Biocon has revenue of INR 16,927.00 crore, net income of INR 385.60 crore, and EPS of INR 4.66.
What is the book value of Biocon?
Biocon has a book value of INR 32.25.
What is the debt-to-equity ratio of Biocon?
Biocon has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Biocon?
Biocon has a price-to-book ratio of 11.78 and a price-to-sales ratio of 4.21.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.